Casdatifan

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

Arcus Biosciences' casdatifan demonstrates superior efficacy profile compared to Merck's Welireg in Phase I/Ib kidney cancer trial, showcasing potential advancement in HIF-2α inhibition.

Arcus Biosciences will showcase safety and efficacy data from the ARC-20 study evaluating casdatifan in previously treated kidney cancer patients at the 2025 ASCO GU Symposium.

Dana-Farber researchers report casdatifan, a novel HIF-2α inhibitor, demonstrates promising clinical activity and tolerability in heavily pretreated clear cell renal cell carcinoma patients.

Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.